Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade… Read more
Calidi Biotherapeutics Inc. (CLDI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.589x
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has a cash flow conversion efficiency ratio of -0.589x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.24 Million) by net assets ($7.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Calidi Biotherapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Calidi Biotherapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Calidi Biotherapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xpon Technologies Group Ltd
AU:XPN
|
1.398x |
|
SANLAM MAROC
BC:SANLAM-MAROC
|
N/A |
|
Havsfrun Investment AB (publ)
ST:HAV-B
|
0.008x |
|
Lion Energy Ltd
AU:LIO
|
-0.111x |
|
Nevada Exploration Inc
OTCQB:NVDEF
|
-0.403x |
|
My Size Inc
NASDAQ:MYSZ
|
-0.085x |
|
ASSURANT
BE:ZAS
|
0.083x |
|
Versus Systems Inc
NASDAQ:VS
|
0.007x |
Annual Cash Flow Conversion Efficiency for Calidi Biotherapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Calidi Biotherapeutics Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.97 Million | $-19.69 Million | -10.007x | -405.41% |
| 2023-12-31 | $-8.23 Million | $-26.98 Million | 3.277x | +1150.74% |
| 2022-12-31 | $-50.44 Million | $-13.21 Million | 0.262x | -23.80% |
| 2021-12-31 | $-22.61 Million | $-7.77 Million | 0.344x | +60.15% |
| 2020-12-31 | $-22.48 Million | $-4.83 Million | 0.215x | -- |